MRFR Year End Sale
Veterinary/Animal Vaccines Market Research Report - Forecast till 2030

Veterinary/Animal Vaccines Market Information: By Type (Livestock Vaccines, Porcine Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines), and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/1994-CR | May 2019 | Region: Global | 133 Pages         

Veterinary/Animal Vaccines Market

Veterinary/Animal Vaccines Market at a CAGR of 9.20% to hit $ 11.1 Billion by 2030

Segmentation

By Type Livestock Vaccines Porcine Vaccines
By Technology Live Attenuated Vaccines Inactivated Vaccines

Key Players

  • Zoetis (US)
  • Virbac SA (France)
  • Merck (US)
  • Phibro Animal Health Corporation (US)
  • Boehringer Ingelheim (Germany)
  • Ceva (France)
  • Elanco (US)

Drivers

  • The increasing rate of pet adoption
  • Rising expenditure on the pet treatment
Speak to Analyst Request a Free Sample

Veterinary/Animal Vaccines Market Overview


The veterinary/animal vaccines market is projected to reach USD 11.1 Billion by 2030 at 9.20% CAGR during the forecast period 2022-2030


The important of veterinary vaccines can’t be understated or ignored. It’s these vaccines that make most farm animals stronger. It also prevents them from getting viruses and bacteria that can be dangerous and/or even deadly for humans if consumed. COVID-19 is a good example of this. It was transmitted from humans to bats when the Chinese ate meat from infected bats in their soups! 

In 2022, Europe had its worst outbreaks of African swine disease. Combating African swine disease, which has killed more than 100 million pigs since 2018, has proven to be more difficult than initially anticipated. The emphasis remained on doing extensive testing to observe how the candidates interact with other ailments or pregnant sows. The inquiry is still clouded by general considerations like how frequently the vaccination would need to be given and whether the vaccine developed in Spain will work similarly well elsewhere. By the end of 2024, the vaccine is expected to be ready for use.


COVID-19 analysis


COVID-19 is to the 21st century what the Bubonic Plague was to the 5th century and the Black Death was to the 14th century - a real destiny and game changer. COVID-19 was initially transmitted to humans from bats in China. It quickly spread across the world. Governments realized that this virus was dangerous and posing a real problem when some of the people who contracted it died. Many more who recovered either got it again or suffered real and long-term health issues.


The veterinary/animal vaccines market suffered immensely because pet owners and farmers were encouraged to keep their animals at home. They were advised against taking their pets to the vet to get strong and effective vaccines like the Pfizer veterinary vaccines. Growth in the veterinary/animal vaccines market is starting to pick up dramatically now that a vaccine for COVID-19 is being widely administered. Demand for animal vaccines is surging because livestock on farms around the world need these to remain healthy. 


Market dynamics


Drivers


As the middle classes around the world explode, so does the preference to keep pets. Most people keep cats and dogs as pets.. These pets need vaccines in order to stay healthy. This is one large driver of growth in the veterinary/animal vaccines market. 


Growing middle classes around the world means that the demand for meat consumption is rising dramatically around the world. This raises the importance of veterinary vaccines because farm animals need to be vaccinated before they are slaughtered for human consumption. This keeps the meat healthier and helps it last longer. It also keeps animals from developing dangerous bacteria, parasites, and viruses that can harm or even kill humans. In fact, according to the international veterinary vaccines and diagnostics conference 2006 the demand for various types of animal vaccines will increase dramatically in later years. 


Opportunities


There are many emerging opportunities in the veterinary/animal vaccines market. Many veterinary clinics are investing heavily in research and development to develop and market more advanced vaccines that will keep animals healthier and stronger and help them live longer. 


Vaccines for animals are also getting a strong boost from technological advancements. It’s advancements in technology that promise to make a new generation of stronger animal vaccines that are much more effective and last longer. 


Research and development will also allow vaccine manufacturers to develop and market hybrid vaccines. These will be much more effective, hence they will be extremely profitable. 


Restraints


All vaccines have side effects. Animal vaccines are no exception. This is a key restraint in the veterinary/animal vaccines market. Most farmers and pet owners are loath to get their animals vaccinated because they are all too aware of the side effects but they are not aware enough of the benefits of these vaccines. Most farmers don’t get their animals vaccinated for this reason. This is the case in developing nations. 


The animal vaccine market is also heavily regulated. This is another factor that’s holding back growth in the veterinary/animal vaccines market. 


Challenges


Some animal vaccines for some segments of animals are very expensive. This factor is a major challenge in the veterinary/animal vaccines market. Animal vaccine manufacturers will also have to find ways to better educate animal owners about the benefits of animal vaccines. 


Technology analysis


Merck is a major American player in the veterinary/animal vaccines market. It became an industry leader by creating a sustainable competitive advantage. Intensive investments in research and development have allowed it to do this. 

In the field of animal research, the value of vaccines has been established significantly. Animals and pets have both been immunized for many years. In the near future, beekeepers might be able to immunize their colonies. As of October 2022, the first honeybee vaccine in the world is being developed by the University of Georgia College of Agricultural and Environmental Sciences (CAES) and Dalan Animal Health.


Segment overview


By type


The veterinary/animal vaccines market can be grouped into the following sub-segments by type:



  • Porcine Vaccines

  • Poultry Vaccine

  • Livestock Vaccine

    • Bovine Vaccines

    • Small Ruminant Vaccines



  • Companion Animal Vaccine

    • Canine Vaccine

    • Feline Vaccine



  • Aquaculture Vaccines

  • Other Animal Vaccines


The attenuated vaccines sub-segment held the highest market share last year because they do a better job of boosting animals’ immune systems than other vaccines do. Also, animals who get attenuated vaccines need fewer booster shots less often. Most booster vaccines are given to animals orally. This makes them less effective in strengthening the animals’ immune systems and keeping them healthier than vaccines that are given by injection. 


The companion animal vaccines are given to cats and dogs. Livestock vaccines tend to be given to farm animals. The livestock vaccine market had the highest market share in 2020. The reason was that these animals tend to be vaccinated more frequently and more often than companion animals. 


By disease


The veterinary/animal vaccines market can be grouped into the following sub-segments by disease:



  • Porcine

  • Poultry

  • Livestock

    • Bovine

    • Small Ruminant



  • Companion Animal

    • Canine

    • Feline



  • Aquaculture


By technology


The veterinary/animal vaccines market can be grouped into the following sub-segments by type:



By Type (Livestock)


The Department of Animal Husbandry and Dairying (DAHD) advised states to immunize cattle and buffaloes with the available Goat pox vaccine on September 20, 2021, despite the fact that lumpy skin disease has already killed almost 1 lakh cattle and infected over 20 lakh animals across 15 states. The only manufacturer of the goatpox vaccine in the nation at the time of authorization was Hester Biosciences in Gujarat; IIL, the Hyderabad-based Brilliant Bio Pharma Pvt Ltd, introduced its goatpox vaccine in December 2021.

Regional analysis


The veterinary/animal vaccines market can be divided into the following geographic regions:



  • North America

  • Asia-Pacific

  • The European Union


North America has the highest market share. The reason is that North Americans tend to have more pets than people in the rest of the world. This is especially true in America. People in the North American region also tend to eat more meat and dairy products than people who live in other parts of the world do. They also tend to drink more milk. All of these need to come from immunized animals to be considered safe for human consumption.


Americans and Canadians, especially, are much more aware of the benefits of animal vaccines than people in the rest of the world are.


The Asia-Pacific region is projected to have the highest CAGR for the years that this report covers. The reason is that more people in Asian nations are adopting cats and dogs as pets - the middle classes are growing and they want to mimic their Western counterparts. The Asia-Pacific region (especially those nations in East Asia) has seen a rise in the number of strange viruses that are transmitted to humans by animals. COVID-19 happens to be one of these.


Asian nations are also investing heavily in animal vaccines both through government efforts and through private enterprise. The result has been the development of animal vaccines that are more effective, stronger, and have more innovative uses. This is needed since meat consumption is rising dramatically throughout the Asia-Pacific region.


Middle East and Africa


In October 2022, SheVax+, a regional livestock vaccination project that was begun in 2019 with funding from the Bill & Melinda Gates Foundation through the Livestock Vaccine Innovation Fund, the International Development Research Centre, and Global Affairs Canada, had achieved great progress. The initiative aims to increase the number of female AHSPs, provide them with training and livestock medications and vaccinations, establish solar-powered refrigerators as a local supply of vaccines, and improve women's access to livestock vaccines. Women can also get information from SheVax+ and its partners about where to get vaccines and veterinary services.


APAC: India


Indian Immunologicals (IIL), a division of the National Dairy Development Board, would invest roughly USD 85 million to build a new animal vaccine production facility in Genome Valley, Hyderabad. According to IIL, one of the largest manufacturers of FMD vaccine globally and a major supplier of the vaccine to the National Animal Disease Control Programme, the greenfield veterinary vaccine facility is intended to be a state-of-the-art fully integrated biosafety level 3 (BSL-3) facility for drug substance production and respective fill-finish.


Competitive landscape


The veterinary/animal vaccines market is very competitive. There are many reasons for this. The first is that there is a lot of money to be made in veterinary/animal vaccines market. The second is that there are relatively few barriers to entry. This especially applies to veterinary vaccine suppliers. Companies are finding that they can survive and create a sustainable competitive advantage only if they invest in research and development to try to create newer generations of innovative animal vaccines that will be more effective, have more innovative uses, and will sell better!


Companies also find that they can stay competitive if they enter into strategic partnerships with other successful companies and/or if they merge with/acquire other successful companies.


Merck is an American company that has been very successful in the veterinary/animal vaccines market. It has managed to create a sustainable competitive advantage by investing heavily in research and development. This has allowed it to develop and market a new generation of effective vaccines which have put the company in a good market position.


List of companies



  • Zoetis (US)

  • Virbac SA (France)

  • Merck (US)

  • Phibro Animal Health Corporation (US)

  • Boehringer Ingelheim (Germany)

  • Ceva (France)

  • Elanco (US) 


Recent developments



  • Many key companies in the veterinary/animal vaccines market have stayed successful by entering into strategic partnerships with other successful companies. They have managed to develop a new vaccine for poultry (chicks to be exact). This is very effective so it has great revenue generation potential.

  • Big companies are partnering up to develop new aquaculture vaccines that will do a better job of protecting aquatic life from diseases.

  • Elanco acquired a new animal vaccine company as part of its expansion strategy


Report overview


The CAGR for the veterinary/animal vaccines market is 9.20%. The veterinary/animal vaccines market is projected to be worth USD 11.1 billion in 2030. The North American region has the largest market share but the Asia-Pacific region has the highest CAGR.



Report Scope:

Report Attribute/Metric Details
  Market Size   11.1 Billion
  CAGR   9.20%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Technology, Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)
  Key Market Opportunities

  • High development opportunities in the upcoming years
  • Technological developments
  •   Key Market Drivers

  • The increasing rate of pet adoption
  • Rising expenditure on the pet treatment
  • High consumption of meat


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    More technological advancement is leading to better and more innovative vaccines

    Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)